The efficacy of margetuximab/magenex can last for several years

Margetuximab, as a new generation of anti-HER2 monoclonal antibody, has attracted widespread attention in the treatment of metastatic HER2-positive breast cancer. Compared with traditional antiHER2 drugs, it has been engineered and optimized in molecular structure, so that it can better activate the patient's own immune system while binding to the HER2 receptor, thereby improving the ability to clear tumor cells. This improvement provides new opportunities to extend disease control for patients who have experienced multiple anti-HER2 regimens.

There is currently no fixed figure for how many years the therapeutic effect can last. Due to the obvious differences among breast cancer patients, factors including genotype, previous medication history, tumor burden, physical condition, and tolerance to treatment will all affect the duration of treatment. It can be seen from overseas clinical data and real-world studies that some patients can achieve more durable disease remission and significantly extend the time to disease progression after receiving margetuximab combined with chemotherapy.

Compared with otherHER2-targeted drugs, the biggest feature of margetuximab is that it enhances its interaction with immune cells by modifying the Fc fragment, making antibody-dependent cell-mediated toxicity (ADCC) more significant. This means that in terms of disease control, it not only relies on directly inhibiting the HER2 signaling pathway, but also works synergistically by stimulating the patient's own immunity. This dual mechanism provides a theoretical basis for patients to prolong the maintenance time of therapeutic effect, and also makes it an important choice in multi-line treatment.

Breast cancer treatment is often a long-term management process, and even if margetuximab is used, it requires comprehensive intervention in combination with chemotherapy, hormone therapy, or other targeted drugs. While the efficacy is maintained, doctors will also closely monitor the patient's adverse reactions and tolerance, and adjust the treatment plan if necessary.

Reference materials:https://www.margenza.com/